Proceedings/Outcome of the 38th Annual General Meeting of the company held on September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech held its 38th AGM on September 30, 2025, via video conferencing from 3:00 PM to 3:35 PM. A total of 76 members attended (6 promoters and 70 public shareholders), along with all six directors, the statutory auditor, and the secretarial auditor. Three items of business were transacted: adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025; re-appointment of Dr. Sankaranarayanan Alangudi as a director (retiring by rotation); and appointment of Mr. Vinay Babu Gade as the Secretarial Auditor. The auditor's report had no qualifications. E-voting was conducted between September 26 and September 29, 2025, and voting results are to be shared with the stock exchange by October 3, 2025.
This is a routine procedural disclosure confirming the AGM was conducted in compliance with regulations. Shareholders should watch for the voting results (due by October 3) to see the level of approval for the financial statements and director re-appointment. The re-appointment of Dr. Alangudi and appointment of a new Secretarial Auditor are standard governance items with no immediate material impact on the stock price.